

Edgar Filing: ANTIGENICS INC /DE/ - Form POS AM

ANTIGENICS INC /DE/
Form POS AM
December 04, 2003

As filed with the Securities and Exchange Commission on November 21, 2003

Registration No. 333-56948

U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

ANTIGENICS INC.
(Exact name of registrant as specified in its charter)

Delaware

06-1562417

(State or other jurisdiction (I.R.S. Employer Identification Number)
of incorporation or organization)

630 FIFTH AVENUE, SUITE 2100, NEW YORK, NEW YORK 10111
(212) 994-8200

(Address, including zip code, and telephone number, including area code,
of registrant's principal executive offices)

GARO H. ARMEN, PH.D.
President and Chief Executive Officer
Antigenics Inc..
630 Fifth Avenue, Suite 2100
New York, New York 10111
(212) 994-8200

(Name, address, including zip code, and telephone number, including
area code, of agent for service)

with copies to:

PAUL KINSELLA
Ropes & Gray LLP
One International Place
Boston, Massachusetts 02110
(617) 951-7000

Edgar Filing: ANTIGENICS INC /DE/ - Form POS AM

EXPLANATORY NOTE

Antigenics Inc. previously registered 458,098 shares of Antigenics common stock, \$0.01 par value per share (the "Shares"), for resale by the State of Wisconsin Investment Board, which had acquired the Shares in connection with Antigenics' acquisition of Aquila Biopharmaceuticals Inc. in November 2000. This Post-Effective Amendment is filed to deregister the 20,000 Shares that remain unsold.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the New York City, New York, on November 21, 2003.

ANTIGENICS INC.

By: /s/ Garo H. Armen, Ph.D.

Garo H. Armen
President and Chief Executive Officer